The Interleukin 17 pipeline drugs market research report outlays comprehensive information on the Interleukin 17 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 17 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Musculoskeletal Disorders, Dermatology, and Respiratory which include the indications Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Ankylosing Spondylitis (Bekhterev’s Disease), Psoriatic Arthritis, Hidradenitis Suppurativa, Unspecified Dermatological Disorders, Idiopathic Pulmonary Fibrosis, and Chronic Obstructive Pulmonary Disease (COPD). It also reviews key players involved in Interleukin 17 targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 17 pipeline targets constitutes close to 58 molecules. Out of which, approximately 56 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 14, 3, 8, 4, 14, and 10 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Interleukin 17 overview
Interleukin-17 (IL-17) is a pro-inflammatory cytokine that plays a crucial role in host defense, inflammation, and autoimmune diseases. It is primarily produced by a subset of CD4+ T helper cells known as Th17 cells, but also by other cell types such as gamma delta T cells, natural killer T cells, and macrophages. IL-17 exerts its effects by binding to its cognate receptor, IL-17RA, which is expressed on a wide range of cells, including epithelial cells, fibroblasts, endothelial cells, and immune cells.
For a complete picture of Interleukin 17’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
